US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,419.51

+26.451.90%

Number of Gainers:2

Number of Losers:1

Number of Flat:- -

PE:- -

High:1,424.04

Open:1,390.56

Low:1,390.55

Close:1,393.07

Loading ...

Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?

Novartis shareholders approve dividend increase to CHF 3.50 per share

Barnes & Noble Education Names New Chief Accounting Officer, General Counsel

MT Newswires Live

Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss

Novartis AG (NVS): Among the Best Undervalued Stocks to Invest In Now

Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?

Bank of America Securities Remains a Buy on Gilead Sciences (GILD)

Novartis Earns Near-Best Overall Rating As Profit Growth Climbs

Pharmaceutical Stocks Hit New Highs Amid Market Volatility

Discover Gilead Sciences And 2 More Stocks That May Be Priced Below Intrinsic Estimates

Simply Wall St.

Gilead Sciences, Inc. : Oppenheimer Raises Target Price to $132 From $115

THOMSON REUTERS

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

Gilead Sciences sets aside $200 million to resolve HIV drug probe

KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4578/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4578"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1419.5145,"timestamp":1741381199999,"preClose":1393.0686,"halted":0,"volume":16860248,"delay":0,"changeRate":0.018984,"change":26.445923,"pbRate":5.836914,"amount":1955549662.014186,"amplitude":0.024037,"prevYearClose":1164.883,"fiveDayClose":1356.2184,"twentyDayClose":1264.0189,"turnoverRate":0.005377,"marketCap":374516049316,"floatMarketCap":363567089388,"peRate":30.498118},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1424.038,"amplitude":0.024037,"preClose":1393.0686,"low":1390.5533,"pbRate":"5.836914","latestPrice":1419.5145,"volume":16860248,"delay":0,"open":1390.5552,"prevYearClose":1164.883,"prevWeekClose":1419.5145,"prevMonthClose":1356.2184,"prevQuarterClose":1164.883,"fiveDayClose":1356.2184,"twentyDayClose":1264.0189,"sixtyDayClose":1194.1743,"secType":"PLATE","market":"US","turnoverRate":0.005377,"peRate":30.498118,"marketCap":374516049316,"floatMarketCap":363567089388,"timestamp":1741381199999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":2,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517448646","title":"Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517448646","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517448646?lang=en_us&edition=fundamental","pubTime":"2025-03-08 16:37","pubTimestamp":1741423020,"startTime":"0","endTime":"0","summary":"Shares of Krystal Biotech KRYS have gained 15.8% in the past month compared with the industry’s growth of 4%. The stock has also outperformed the industry and the sector in this timeframe.Last month, KRYS reported fourth-quarter 2024 results. While earnings beat estimates, sales missed the same. Nonetheless, shares surged post the quarterly release, mostly due to the strong uptake of Vyjuvek and encouraging pipeline progress.Krystal recorded Vyjuvek sales of $290.5 million, up from $50.7 million in 2023.It has made steady progress, securing access and reimbursement for Vyjuvek since its launch in the United States.As of February 2025, Krystal secured more than 510 reimbursement approvals for Vyjuvek in the United States and continues to maintain strong access nationwide, including positive access determinations for 97% of lives covered under commercial and Medicaid plans.Krystal is looking to get Vyjuvek approved in other geographies as well.In October, Krystal Biotech filed a new drug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/krystal-biotech-rises-15-8-083700261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","LU1585245621.USD","LU2089984988.USD","BK4588","LU1430594728.SGD","BK4578","IE00BZ1G4Q59.USD","BK4139","LU1839511570.USD","IE00B7SZLL34.SGD","BMRN","IE00B3T34201.USD","LU1066053197.SGD","IE0002270589.USD","LU1571399168.USD","LU1066051498.USD","LU0320765992.SGD","BK4583","BK4585","BK4566","BK4532","KRYS","BK4568","LU2087621335.USD","IE00B19Z3B42.SGD","LU0058720904.USD","GILD","BK4550","LU0889565916.HKD","LU0234570918.USD","LU0289739699.SGD","LU2468319806.SGD","IE00BSNM7G36.USD","LU0109394709.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2517439100","title":"Novartis shareholders approve dividend increase to CHF 3.50 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2517439100","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517439100?lang=en_us&edition=fundamental","pubTime":"2025-03-07 22:26","pubTimestamp":1741357578,"startTime":"0","endTime":"0","summary":"Novartis (NVS) shareholders agreed to the board of directors’ recommendations for all proposed resolutions at the company’s Annual General Meeting,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-shareholders-approve-dividend-increase-to-chf-3-50-per-share?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-shareholders-approve-dividend-increase-to-chf-3-50-per-share?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE0009355771.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0211331839.USD","BK4007","NVS","BK4578","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4588","BK4532","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2517611443","title":"Barnes & Noble Education Names New Chief Accounting Officer, General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2517611443","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517611443?lang=en_us&edition=fundamental","pubTime":"2025-03-07 07:07","pubTimestamp":1741302440,"startTime":"0","endTime":"0","summary":"Barnes & Noble Education  late Thursday disclosed two executive appointments, naming Gary Luster as chief accounting officer and Christopher Neumann as general counsel and corporate secretary.Neumann joins Barnes & Noble Education from Six Flags , where he held the same legal leadership roles. Luster previously worked for several large retailers, including Capri Holdings  and Tiffany, as well as the former consumer health division at Novartis .Both appointments took effect Monday, according to the company.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0002141913.USD","NVS","FUN.AU","LU0211331839.USD","CPRI","IE00B2B36J28.USD","BNED","BK4200","BK4590","BK4216","BK4585","IE00B4R5TH58.HKD","IE0009355771.USD","BK4578","IE00BJT1NW94.SGD","BK4532","BK4007","IE00BFTCPJ56.SGD","FUN","BK4588","IE00BJJMRZ35.SGD","BK4202"],"gpt_icon":1},{"id":"2517988321","title":"Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2517988321","media":"Benzinga","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517988321?lang=en_us&edition=fundamental","pubTime":"2025-03-07 00:29","pubTimestamp":1741278558,"startTime":"0","endTime":"0","summary":"Telemedicine operator Teladoc Health Inc  has entered a pharmacy integration agreement with Eli Lilly And Co's  LillyDirect, a direct-to-consumer pharmacy partner, to streamline access to Zepbound  for members of Teladoc's Comprehensive Weight Care Program.Last year, Eli Lillyannounced anewwebsite allowing patients to get a prescription for weight loss through a telehealth provider,marking an industry first.The collaboration aims to provide affordable and safe options for individuals without insurance coverage for GLP-1 medications used for obesity treatment.Under the agreement, eligible Teladoc Health members prescribed Zepbound by their provider will have the medication delivered directly to their homes via LillyDirect's digital healthcare platform.Also Read: Teladoc Stock Gains As Amazon Partnership Fuels Push for Consumer-Centric Healthcare. Teladoc's Comprehensive Weight Care and Primary360 teams will have full visibility into each stage of the fulfillment process, including dispe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/teladoc-health-partners-eli-liilys-162918087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJJMRZ35.SGD","LU2112291526.USD","SG9999014906.USD","LU2237443465.HKD","LU1064131342.USD","LU0672654240.SGD","LU0820561909.HKD","LU2361044949.HKD","NVS","LU0058720904.USD","LU0006306889.USD","LU2602419157.SGD","IE0004445239.USD","LU0097036916.USD","LU0882574139.USD","LU1868836914.USD","LU2491050071.SGD","IE00BJLML261.HKD","LU1057294990.SGD","LU0079474960.USD","LU0203201768.USD","LU1868836591.USD","LU1983299246.USD","LU2361045086.USD","SGXZ81514606.USD","LU2491050154.USD","LU1720051108.HKD","LU1551013425.SGD","LU2211815571.USD","LU0211331839.USD","SGXZ99366536.SGD","LU1974910355.USD","IE00BK4W5L77.USD","LU2063271972.USD","IE00B2B36J28.USD","LU1035775433.USD","IE0002141913.USD","LU1623119135.USD","LU1267930730.SGD","SGXZ57979304.SGD","BK4548","TDOC","LU1988902786.USD","LU1093756168.USD","IE00B1BXHZ80.USD","BK4578","SG9999015945.SGD","LLY","LU2360106947.USD","BK4599"],"gpt_icon":1},{"id":"2517096929","title":"Novartis AG (NVS): Among the Best Undervalued Stocks to Invest In Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2517096929","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517096929?lang=en_us&edition=fundamental","pubTime":"2025-03-06 04:43","pubTimestamp":1741207388,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look at where Novartis AG  stands against the other undervalued stocks.While talking about how the Fed might react to the tariffs, Fisher mentioned that it is a little too early to guess. The Fed is bringing inflation down and we are getting closer to the 2% target, however, at the same time tariff increases the cost of doing business, which might slow down the economy and tickle up inflation. To conclude Fisher noted that tariffs won’t be digested quickly and will take time.For this article, we used the Finviz stock screener, Yahoo Finance, and Seeking Alpha. Using the screener we aggregated a list of stocks trading below the forward P/E of 15 and earnings growth expectations this year. Next, we cross-checked the Forward P/E from Seeking Alpha and Earnings growth from Yahoo Finance. Lastly, after sorting our list by market capitalization, we ranked the stock","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-ag-nvs-among-best-204308512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B4R5TH58.HKD","IE0009355771.USD","BK4210","US3Y.BOND","BK4578","BK4532","US30Y.BOND","IE00BJT1NW94.SGD","LU0211331839.USD","US6M.BOND","US5Y.BOND","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4007","BK4588","IE0002141913.USD","IE00BJJMRZ35.SGD","US7Y.BOND","NVS","US12M.BOND","US2Y.BOND","BK4585","US10Y.BOND","AG"],"gpt_icon":0},{"id":"2517949629","title":"Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517949629","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517949629?lang=en_us&edition=fundamental","pubTime":"2025-03-05 22:15","pubTimestamp":1741184103,"startTime":"0","endTime":"0","summary":"Have you been paying attention to shares of Gilead Sciences ?Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the previous session. Gilead Sciences has gained 24.2% since the start of the year compared to the 6% move for the Zacks Medical sector and the 6% return for the Zacks Medical - Biomedical and Genetics industry.The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on February 11, 2025, Gilead reported EPS of $1.9 versus consensus estimate of $1.67.For the current fiscal year, Gilead is expected to post earnings of $7.86 per share on $28.55 billion in revenues. This represents a 70.13% change in EPS on a -0.7% change in revenues. For the next fiscal year, the company is expected to earn $8.17 per share on $29.7 billion in revenues. This represents a year-over-year change of 3.9% and 4.01%,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-inc-gild-hits-141503605.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2087621335.USD","BK4007","IE00BSNM7G36.USD","BK4568","IE00B3T34201.USD","IE00BKVL7J92.USD","LU0320765992.SGD","BK4139","BK4585","IE00BN0W2T93.GBP","LU1430594728.SGD","BK4583","LU0109394709.USD","LU0889565916.HKD","BK4566","IE0002270589.USD","LU1839511570.USD","LU1066053197.SGD","JAZZ","LU2468319806.SGD","LU1585245621.USD","IE00BZ1G4Q59.USD","BK4578","LU1066051498.USD","BK4588","LU0058720904.USD","LU1571399168.USD","BK4550","GILD","LU0823416689.USD","IE00B19Z3581.USD","LU0234570918.USD","IE00BN0W2W23.USD","LU0289739699.SGD","LU2089984988.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE00BN0W2V16.EUR","BK4533","BK4532"],"gpt_icon":0},{"id":"2517991313","title":"Bank of America Securities Remains a Buy on Gilead Sciences (GILD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517991313","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517991313?lang=en_us&edition=fundamental","pubTime":"2025-03-05 19:57","pubTimestamp":1741175855,"startTime":"0","endTime":"0","summary":"In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-buy-on-gilead-sciences-gild?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-buy-on-gilead-sciences-gild?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","LU0130102774.USD","LU0256863811.USD","LU1880398554.USD","LU1162221912.USD","LU1201861165.SGD","IE00BBT3K403.USD","BK4585","LU0648000940.SGD","LU1066051498.USD","BK4139","LU1894683264.USD","LU0058720904.USD","IE00BKVL7J92.USD","LU1791807156.HKD","LU1201861249.SGD","LU0109394709.USD","BK4568","LU0053666078.USD","LU0417517546.SGD","LU2133065610.SGD","LU0256863902.USD","LU0130103400.USD","LU1668664300.SGD","LU2129689605.HKD","BK4550","LU1880398471.USD","LU1571399168.USD","LU2087621335.USD","LU0289739699.SGD","LU0971096721.USD","BK4583","LU2089984988.USD","BK4532","LU1280957306.USD","BK4578","LU0208291251.USD","GILD","BK4504","IE00BLSP4239.USD","BK4588","LU1363072403.SGD","IE00BLSP4452.SGD","LU0098860793.USD","LU0170899867.USD","LU1496350171.SGD","LU2129689431.USD","LU1883839398.USD","LU0320765992.SGD","BAC"],"gpt_icon":0},{"id":"2517924507","title":"Novartis Earns Near-Best Overall Rating As Profit Growth Climbs","url":"https://stock-news.laohu8.com/highlight/detail?id=2517924507","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517924507?lang=en_us&edition=fundamental","pubTime":"2025-03-05 16:00","pubTimestamp":1741161600,"startTime":"0","endTime":"0","summary":"On Wednesday,  Novartis ADR got an upgrade for its IBD SmartSelect Composite Rating from 93 to 96.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2018/04/STOCK-Novartis-02-shutter-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/04/STOCK-Novartis-02-shutter-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/novartis-adr-receives-composite-rating-upgrade/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4007","IE00B2B36J28.USD","LU0320765992.SGD","IE0002141913.USD","BK4585","IE00BJT1NW94.SGD","IE00BN0W2T93.GBP","LU0109394709.USD","LU0889565916.HKD","JAZZ","BK4578","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4588","IE00BFTCPJ56.SGD","NVS","PAHC","LU0823416689.USD","IE00B4R5TH58.HKD","LU0211331839.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","BK4533","BK4532"],"gpt_icon":0},{"id":"2517398310","title":"Pharmaceutical Stocks Hit New Highs Amid Market Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2517398310","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517398310?lang=en_us&edition=fundamental","pubTime":"2025-03-05 01:34","pubTimestamp":1741109640,"startTime":"0","endTime":"0","summary":"The stock market has a way of proving the masses wrong.After all the chatter about the new administration’s potentially adverse impact on pharmaceutical stocks and related industries, the broader health care sector is leading the charge in 2025.Following the latest market volatility, the S&P 500 is now in negative territory on the year. It’s somewhat surprising to peak behind the curtain and see that 9 of 11 S&P sectors remain green.The price action in the stock market has been fast and furious as investors repositioned their portfolios for the new year. Sector rotation has been on full display, with institutions foregoing growth and technology positions and shifting to more defensive areas like staples, health care and utilities.Historical research studies suggest that approximately half of a stock’s price appreciation is due to its industry grouping. In fact, the top 50% of Zacks Ranked Industries","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharmaceutical-stocks-hit-highs-amid-173400932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2087621335.USD","BK4139","LU1571399168.USD","LU1585245621.USD","LU2089984988.USD","LU0058720904.USD","BK4550","IE00B7SZLL34.SGD","GILD","LU2468319806.SGD","BK4568","LU0289739699.SGD","BK4578","LU1066053197.SGD","LU0889565916.HKD","IE00BZ1G4Q59.USD","IE00B3T34201.USD","IE0002270589.USD","IE00BSNM7G36.USD","IE00B19Z3581.USD","LU1839511570.USD","BK4532","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU0234570918.USD","LU0320765992.SGD","LU0109394709.USD","BK4585","BK4583","BK4566","LU1430594728.SGD","BK4588","LU1066051498.USD"],"gpt_icon":0},{"id":"2517817604","title":"Discover Gilead Sciences And 2 More Stocks That May Be Priced Below Intrinsic Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517817604","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517817604?lang=en_us&edition=fundamental","pubTime":"2025-03-05 01:08","pubTimestamp":1741108082,"startTime":"0","endTime":"0","summary":"As the U.S. market grapples with the impact of newly imposed tariffs and a broad-based sell-off, investors are keenly assessing opportunities that may arise from these turbulent conditions. In such an environment, identifying stocks that appear to be undervalued based on intrinsic estimates can provide potential avenues for investment, as they might offer resilience against broader economic challenges.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Gilead Sciences shows potential as an undervalued stock based on cash flows, trading at US$115.99, significantly below its estimated fair value of US$228.07. Despite high debt levels and a current profit margin dip to 1.7%, earnings are forecasted to grow significantly by 23.6% annually over the next three years, outpacing the broader U.S. market's growth expectations of 14%. Recent regulatory advancements for key products like lenacapavir may bolster future cash flows.Overview: Intuit Inc. offers financial management, co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/discover-gilead-sciences-2-more-170802498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BZ1G4Q59.USD","LU1814569148.SGD","GILD","BK4139","SSB","GB00BDT5M118.USD","SMWB","LU0466842654.USD","LU1093756168.USD","BK4533","BK4581","IE00B19Z3581.USD","LU1585245621.USD","LU0823416689.USD","LU0820561818.USD","LU2237443549.SGD","BK4568","LU0672654240.SGD","LU1791807156.HKD","SG9999018865.SGD","LU0114720955.EUR","LU1280957306.USD","LU2324357040.USD","SG9999014898.SGD","SGXZ99366536.SGD","LU2237443465.HKD","LU0256863811.USD","DFS","LU1988902786.USD","IE00B4R5TH58.HKD","JBTM","LU0471298694.HKD","WK","LU2087621335.USD","LU1127390331.HKD","BK4578","LU1430594728.SGD","LU2237438978.USD","INTU","IE00BFTCPJ56.SGD","LU1839511570.USD","LU2237443895.HKD","BC","LLY","LU0689472784.USD","BK4516","LU1868837136.USD","LU1291159041.SGD","IE00BJJMRZ35.SGD","LU0128526141.USD","LU0079474960.USD"],"gpt_icon":1},{"id":"2516676930","title":"Gilead Sciences, Inc. : Oppenheimer Raises Target Price to $132 From $115","url":"https://stock-news.laohu8.com/highlight/detail?id=2516676930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516676930?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:15","pubTimestamp":1741094114,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nAZN3HPGL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","BK4139","LU1066051498.USD","LU1066053197.SGD","LU2087621335.USD","LU1839511570.USD","LU0289739699.SGD","BK4585","LU2468319806.SGD","BK4583","IE00B3T34201.USD","LU1585245621.USD","BK4550","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU0058720904.USD","LU2089984988.USD","IE0002270589.USD","LU0889565916.HKD","LU1571399168.USD","IE00BZ1G4Q59.USD","BK4588","IE00B19Z3581.USD","LU0320765992.SGD","GILD","IE00B7SZLL34.SGD","BK4568","LU0234570918.USD","IE00BKVL7J92.USD","BK4578","LU1430594728.SGD","BK4566","BK4532"],"gpt_icon":0},{"id":"2517600123","title":"Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction","url":"https://stock-news.laohu8.com/highlight/detail?id=2517600123","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517600123?lang=en_us&edition=fundamental","pubTime":"2025-03-04 16:00","pubTimestamp":1741075200,"startTime":"0","endTime":"0","summary":"A Relative Strength Rating upgrade for Novartis shows improving technical performance. Will it continue?","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2019/01/Stock-DrugsResearch-09-shutter-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2019/01/Stock-DrugsResearch-09-shutter-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/novartis-adr-trying-to-close-in-on-key-technical-benchmark-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4578","BK4532","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","PAHC","IE0009355771.USD","BK4585","IE00BFTCPJ56.SGD","RS","IE00B2B36J28.USD","BK4007","BK4006","BK4588","NVS"],"gpt_icon":0},{"id":"2516958616","title":"Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts","url":"https://stock-news.laohu8.com/highlight/detail?id=2516958616","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516958616?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:50","pubTimestamp":1741042206,"startTime":"0","endTime":"0","summary":"In the latest market close, Gilead Sciences  reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow experienced a drop of 1.48%, and the technology-dominated Nasdaq saw a decrease of 2.64%.The HIV and hepatitis C drugmaker's shares have seen an increase of 17.6% over the last month, surpassing the Medical sector's gain of 1.11% and the S&P 500's loss of 1.26%.The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings per share  are projected to be $1.73, reflecting a 231.06% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $6.78 billion, indicating a 1.36% growth compared to the corresponding quarter of the prior year.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research show","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-rises-market-225006380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4578","IE00B7SZLL34.SGD","LU2089984988.USD","BK4566","LU1066053197.SGD","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","LU1839511570.USD","LU0289739699.SGD","GILD","LU0234570918.USD","LU2087621335.USD","BK4585","IE00BKVL7J92.USD","BK4583","BK4568","LU2468319806.SGD","LU1585245621.USD","LU0058720904.USD","LU1066051498.USD","LU0109394709.USD","LU0320765992.SGD","BK4588","IE00BSNM7G36.USD","BK4532","LU1571399168.USD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU0889565916.HKD","BK4139","BK4550","LU1430594728.SGD"],"gpt_icon":0},{"id":"2516653634","title":"Gilead Sciences sets aside $200 million to resolve HIV drug probe","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653634","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653634?lang=en_us&edition=fundamental","pubTime":"2025-03-04 00:18","pubTimestamp":1741018712,"startTime":"0","endTime":"0","summary":"Gilead Sciences sets aside $200 million to resolve HIV drug probeBy Luc Cohen NEW YORK, March 3 (Reuters) - Gilead Sciences GILD.O set aside $200 million for a potential settlement with federal prosec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL2N3PM0KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0234570918.USD","LU1066053197.SGD","LU2087621335.USD","BK4578","BK4532","BK4550","LU2468319806.SGD","IE00BSNM7G36.USD","GILD","LU0289739699.SGD","IE00B7SZLL34.SGD","BK4566","BK4588","IE00B3T34201.USD","LU1066051498.USD","IE00BKVL7J92.USD","BK4568","LU0109394709.USD","LU0320765992.SGD","LU0058720904.USD","LU2089984988.USD","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","LU1430594728.SGD","LU1571399168.USD","BK4585","IE0002270589.USD","LU1839511570.USD","BK4583","LU0889565916.HKD","LU1585245621.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2516656745","title":"KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516656745","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516656745?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:59","pubTimestamp":1741017540,"startTime":"0","endTime":"0","summary":"Krystal BiotechKRYS announced that the European Medicines Agency'sCommittee for Medicinal Products for Human Use  has adopted a positive opinion recommending the approval of Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa . The intended DEB patient population includes those who have mutations in the COL7A1 gene starting from birth.DEB is a rare and severe monogenic disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1. Vyjuvekis a non-invasive, topical, redosable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds.In the past three months, shares of Krystal Biotech have plunged 18.3% compared with the industry’s 0.6% decline.More on CHMP’s Positive Opinion on Vyjuvek’s EU Approval. The positive CHMP opinion recommending the approval of Vyjuvekfor the DEB indication in the EU is based on the results of Krystal Biotech’s phase I/II GEM-1 and phase","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/krys-gets-positive-chmp-opinion-155900015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKVL7J92.USD","LU2065171402.SGD","CHMP","BK4550","IE0002270589.USD","IE00B7SZLL34.SGD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4588","LU0289739699.SGD","KRYS","LU1066053197.SGD","BK4139","IE00B3T34201.USD","LU0889565916.HKD","LU2065170008.USD","BK4566","BK4532","IE00B19Z3581.USD","LU0109394709.USD","LU0234570918.USD","LU1066051498.USD","BK4585","LU2065171311.SGD","LU1585245621.USD","BK4087","LU2087621335.USD","IE00B19Z3B42.SGD","BK4568","LU0058720904.USD","BMRN","FOLD","LU1430594728.SGD","BK4156","BK4578","LU2065169927.USD","BK4583","LU1571399168.USD","LU1839511570.USD","IE00BSNM7G36.USD","GILD","LU2089984988.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2516653171","title":"Novartis Gets CHMP Opinion for Label Expansion of Fabhalta","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653171","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653171?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:39","pubTimestamp":1741012740,"startTime":"0","endTime":"0","summary":"Novartis NVS announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency has adopted a positive opinion for the label expansion of Fabhalta ((iptacopan).Fabhalta is an oral, Factor B inhibitor of the alternative complement pathway 6-7.The CHMP recommended granting a marketing authorization to Fabhalta for the treatment of adults with C3 glomerulopathy , an ultra-rare, progressive kidney disease with no currently approved treatments.A final decision from the European Commission  is expected in two months.The CHMP’s positive opinion is based on robust data from APPEAR-C3G, a randomized placebo-controlled phase III study. The study showed patients treated with Fabhalta, in addition to supportive care, achieved a statistically significant and clinically meaningful 35.1% reduction in proteinuria  at 6 months when compared to placebo.A potential approval will make Fabhalta the only drug indicated to target the underlying cause of C3G.Shares of Novartis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-gets-chmp-opinion-label-143900090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","LU0234570918.USD","LU1585245621.USD","GILD","LU1839511570.USD","IE00B3T34201.USD","IE00BJT1NW94.SGD","LU2087621335.USD","LU0289739699.SGD","IE0002141913.USD","CHMP","LU1430594728.SGD","LU2089984988.USD","IE00BZ1G4Q59.USD","EC","LU0058720904.USD","IE00BFTCPJ56.SGD","IE0002270589.USD","IE00BJJMRZ35.SGD","BK4139","BK4588","LU2468319806.SGD","BK4583","IE00B7SZLL34.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU0211331839.USD","LU0320765992.SGD","LU1066051498.USD","IE00BSNM7G36.USD","BK4087","BK4201","LU1066053197.SGD","BK4585","BK4550","BK4532","BMRN","IE00B19Z3B42.SGD","LU1571399168.USD","NVS","BK4568","IE00B4R5TH58.HKD","IE00BKVL7J92.USD","BK4007","LU0889565916.HKD","BK4566","BK4578","LU0109394709.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":1,"totalSize":60}]}}